This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Interferon β (IFNβ) is an approved immunomodulatory treatment of multiple sclerosis (MS). However, treatment with type I interferons may induce autoimmune diseases.1 This has mainly been shown for interferon α, but is not uncommon for IFNβ. Published results on humoral organ autoimmunity in IFNβ-treated patients with MS are not unequivocal at present.2,3
We therefore measured autoantibodies (AAbs) against major thyroid (thyroperoxidase [TPO] and thyroglobulin [Tg]) and pancreatic β-cell (glutamic acid decarboxylase [GAD65]) autoantigens in a large cohort of patients with MS treated with IFNβ or IFNβ treatment naïve. In the former, the presence of IFNβ neutralizing antibody (NABs) was correlated to AAbs seropositivity, as NABs may be an indicator of an activated humoral immune response.
Methods.
AAbs were determined by commercial radioligand assays against GAD65 (Medipan, Leipzig, Germany) and against TPO and Tg (BRAHMS, Hennigsdorf, Germany) with predefined cutoff levels (table) in 209 IFNβ-treated patients with MS and an age- and sex-matched control group of 57 IFNβ-naïve patients with MS. In the treated patients, presence of NABs was assessed by capture ELISA and ex vivo MxA real time rtPCR 12 hours after administration of IFNβ as described previously.4 Briefly, detection of binding antibodies by ELISA and demonstration of inhibition of MxA mRNA induction in peripheral blood lymphocytes at least once deemed a sample NAB positive. Statistical tests were performed using GraphPad Prism 4.0.
- In this window
- In a new window
Table Demographics (upper part) and autoantibody results (lower part) in …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.